DOLAMA study-Reference-Cited by-同舟云学术

DOLAMA study

Published:2019-08 Issue:32 Volume:98 Page:e16813
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Hidalgo-Tenorio Carmen,Cortés Luis López,Gutiérrez Alicia,Santos Jesús,Omar Mohamed,Gálvez Carmen,Sequera Sergio,Jesús Samantha Eisabeth De,Téllez Franciso,Fernández Elisa,García Coral,Pasquau Juan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference27 articles.

1. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada;Samji;PLoS One,2013

2. Nuke-sparing regimens for the long-term care of HIV infection;Pasquau;AIDS Rev,2015

3. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial;Arribas;Lancet Infect Dis,2015

4. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial;Perez-Molina;Lancet Infect Dis,2015

5. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M);Di Giambenedetto;J Antimicrob Chemother,2017

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation;Viruses;2024-08-30

2. Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis;Open Forum Infectious Diseases;2024-06-28

3. One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study;Open Forum Infectious Diseases;2024-06-20

4. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine;Journal of Antimicrobial Chemotherapy;2024-03-28

5. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study;Open Forum Infectious Diseases;2024-03-18